Literature DB >> 8010983

Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity.

J B Custódio1, T C Dinis, L M Almeida, V M Madeira.   

Abstract

Tamoxifen (TAM) is the antiestrogen most widely used in the chemotherapy and chemoprevention of breast cancer. It has been reported that TAM and its more active metabolite 4-hydroxytamoxifen (OHTAM) induce multiple cellular effects, including antioxidant actions. Here sarcoplasmic reticulum membranes (SR) were used as a simple model of oxidation to clarify the antioxidant action type and mechanisms of these anticancer drugs on lipid peroxidation induced by Fe2+/ascorbate and peroxyl radicals generated by the water-soluble 2,2'-azobis(2-amidinopropane)dihydrochloride (AAPH) and by the lipid-soluble 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN). Peroxidation was monitored by different assay systems, namely cis-parinaric acid (PnA) fluorescence quenching, production of thiobarbituric acid-reactive substances, polyunsaturated fatty acids (PUFA) degradation and oxygen consumption. TAM and OHTAM are efficient inhibitors of lipid peroxidation induced by Fe2+/ascorbate and strong intramembraneous scavengers of peroxyl radicals generated either in the water or lipid phases by AAPH and AMVN, respectively. However, these drugs are not typical chain-breaking antioxidant compounds as compared with vitamin E. Additionally, their antioxidant effectiveness enhances the protective capacity of vitamin E against lipid peroxidation induced by AMVN. OHTAM is a more powerful intramembraneous inhibitor of lipid peroxidation as compared with TAM; this effectiveness not correlating with alterations on membrane fluidity may be due to the presence of a hydrogen-donating HO-group in the OHTAM molecule and its preferential location in the outer bilayer regions where it can donate the hydrogen atom to quench free radicals capable of initiating the membrane oxidative degradation. The stronger OHTAM intramembraneous scavenger capacity over TAM also correlates with its higher partition in biomembranes. Therefore, the strong peroxyl radical scavenger activity of OHTAM in the hydrophobic membrane phase may putatively contribute to the mechanisms of cytostatic and chemopreventive action of its promoter TAM on development of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8010983     DOI: 10.1016/0006-2952(94)90073-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

Review 1.  Volume-regulated anion channel--a frenemy within the brain.

Authors:  Alexander A Mongin
Journal:  Pflugers Arch       Date:  2015-12-01       Impact factor: 3.657

2.  Combined efficacy of tamoxifen and coenzyme Q10 on the status of lipid peroxidation and antioxidants in DMBA induced breast cancer.

Authors:  Selvanathan Saravana Perumal; Palanivelu Shanthi; Panchanadham Sachdanandam
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

3.  An esterification protocol for cis-parinaric acid-determined lipid peroxidation in immune cells.

Authors:  S O McGuire; M R James-Kracke; G Y Sun; K L Fritsche
Journal:  Lipids       Date:  1997-02       Impact factor: 1.880

4.  Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.

Authors:  Cristiana T Trinconi; Juliana Q Reimão; Jenicer K U Yokoyama-Yasunaka; Danilo C Miguel; Silvia R B Uliana
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

5.  Tamoxifen is a potent antioxidant modulator for sperm quality in patients with idiopathic oligoasthenospermia.

Authors:  Li Guo; Jun Jing; Yu-Ming Feng; Bing Yao
Journal:  Int Urol Nephrol       Date:  2015-07-28       Impact factor: 2.370

6.  The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen.

Authors:  Filomena S G Silva; Mariana P C Ribeiro; Maria S Santos; Petronila Rocha-Pereira; Alice Santos-Silva; José B A Custódio
Journal:  J Bioenerg Biomembr       Date:  2013-06-19       Impact factor: 2.945

7.  Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates.

Authors:  Foster Birnbaum; Asuka Eguchi; Gaspard Pardon; Alex C Y Chang; Helen M Blau
Journal:  NPJ Regen Med       Date:  2022-03-18

8.  Angiotensin II (AT1) receptors and NADPH oxidase regulate Cl- current elicited by beta1 integrin stretch in rabbit ventricular myocytes.

Authors:  David M Browe; Clive M Baumgarten
Journal:  J Gen Physiol       Date:  2004-09       Impact factor: 4.086

9.  Leishmania is not prone to develop resistance to tamoxifen.

Authors:  Adriano C Coelho; Cristiana T Trinconi; Luisa Senra; Jenicer K U Yokoyama-Yasunaka; Silvia R B Uliana
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-06-17       Impact factor: 4.077

10.  Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.

Authors:  Sara Nagy; Patricia Hafner; Simone Schmidt; Daniela Rubino-Nacht; Sabine Schädelin; Oliver Bieri; Dirk Fischer
Journal:  Trials       Date:  2019-11-21       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.